Ning Li

机构：Tianjin Medical University Cancer Institute and Hospital, Zhengzhou University, North China University of Science and Technology Affiliated Hospital · ORCID：0000-0002-0068-1622

发表论文 130 篇 · 总被引 1437 次 · h-index 17

代表论文

• Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II) (2025 · Med · 被引 20)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Patient-derived tumor organoids for cancer immunotherapy: culture techniques and clinical application (2025 · Investigational New Drugs · 被引 18)
• Kidney hepcidin protects the collecting duct against ferroptosis in ischemia/reperfusion-induced acute kidney injury (2025 · Kidney International · 被引 10)
• A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer (2025 · Scientific Reports · 被引 9)
• Targeting KRAS in colorectal cancer (Review) (2025 · Molecular and Clinical Oncology · 被引 6)